Categories: News

Reliefband® Launches Interchangeable Smart Watch Bands to Extend Compatibility to Apple and Samsung Watches

HORSHAM, Pa., Oct. 28, 2021 /PRNewswire-PRWeb/ — Reliefband, an innovator in wearable technology that prevents and treats nausea and vomiting symptoms, launched new Reliefband® Sport Watch Connectors designed specifically for Apple and Samsung watch owners. Available now, the new watch bands are priced at $29.99 each and offered in two color choices (grey or black). The watch bands can be configured to seamlessly attach to an Apple or Samsung watch. With this interchangeable band, an Apple or Samsung watch is situated on top of a user’s wrist with the Reliefband Sport® aligned on the underside of the wrist so it can deliver side effect-free therapy.

Launched last quarter, Reliefband® Sport is a new waterproof wearable therapeutic device that prevents and treats nausea and vomiting associated with motion sickness, morning sickness from pregnancy, anxiety, hangovers, physician-diagnosed migraines, chemotherapy, and as an adjunct to antiemetics in treating post-operative nausea.

Reliefband Sport® is a clinically proven wearable which includes a built-in rechargeable battery that, when fully charged, will last 30 hours on the medium intensity level. Six intensity levels can be quickly toggled allowing users to find the precise setting that’s optimal for their needs at any moment. With the Sport model’s smart sensing technology, the device will turn off after 60 seconds if skin contact is not detected in order to preserve battery life.

The result of more than 20 years of clinical research, Reliefband’s FDA-cleared, patented technology uses accurately programmed pulses with a highly specific waveform, frequency, and intensity to stimulate the median nerve on the underside of the wrist. This precise activity uses the body’s natural neural pathways to block waves of nausea produced by the stomach.

Reliefband will demonstrate Reliefband Sport® and new Reliefband® Sport Watch Connectors at this week’s Pepcom’s Holiday Spectacular! media event.

About Reliefband®

Reliefband is a world leader in neuromodulation and wearable technology. The company’s patented, clinically proven wearable solution quickly prevents and effectively treats nausea and vomiting. Its unique, FDA-cleared neuromodulation technology was originally developed for use in hospitals and alters nerve activity through targeted delivery of gentle pulses to the underside of the wrist to “turn off” feelings of nausea and vomiting. Reliefband is a drug-free alternative that eliminates the discomfort associated with nausea and vomiting. The Reliefband wearable solution has been an industry leader for more than 20 years and is available OTC, at Reliefband.com and Amazon.com. For more information, visit http://www.Reliefband.com.

Media Contact

Mark Tordik, Reliefband, +1 732-763-3078, mtordik@broadpathpr.com

 

SOURCE Reliefband

Staff

Recent Posts

Glow Lifetech Grants Stock Options

Toronto, Ontario--(Newsfile Corp. - December 27, 2024) - Glow Lifetech Corp. (CSE: GLOW) (OTC Pink:…

5 hours ago

Inspira™ Announces Pricing of $3.2M Private Placement by New and Existing Investors of the Company

RA'ANANA, Israel, Dec. 27, 2024 /PRNewswire/ -- Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ: IINN), (NASDAQ:…

5 hours ago

In-Depth Analysis of BGM Group: Innovating Pharmaceuticals and Insurance through AI

CHONGQING, China, Dec. 27, 2024 /PRNewswire/ -- BGM Group Ltd. (Stock Code: BGM) has successfully acquired…

5 hours ago

NAVIGANTIS VASCO™ Robotic Platform Used with First Patients Enrolled in Neurovascular Study

MIAMI, Dec. 27, 2024 /PRNewswire/ -- Navigantis Inc. announced today the first successful neurovascular clinical cases…

5 hours ago

Biotricity Produces Largest Inventory in its History to Meet Accelerated Demand

Company Receives Capital Needed from its Term Lender and Existing Investors to Reach Profitability without…

5 hours ago

Vor Bio Announces $55.6 Million Private Placement

Intend to announce updated clinical data from Phase 1/2 VBP301 trial of VCAR33ALLO in the…

8 hours ago